Becton Dickinson to licence Med-Design's safety needle:
This article was originally published in Clinica
Becton Dickinson has gained exclusive licensing rights to Med-Design's retractable needle technology, which prevents accidental needlestick injuries. The deal will provide Med-Design, Ventura, California, with a multi-million dollar up-front payment and royalties. Becton will also make a $1.5 million equity investment in Med-Design through the purchase of 300,000 shares at $5 per share. Becton will be entitled to one seat on Med-Design's board.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.